Orion Focus Panel (gene-tech) at Chughtai Lab

Orion Focus Panel (gene-tech) at Chughtai Lab

The Orion Focus Panel (gene-tech) at Chughtai Lab represents a significant advancement in molecular diagnostics and personalized medicine in Pakistan. This specialized genetic test utilizes state-of-the-art Next-Generation Sequencing (NGS) technology to analyze specific genomic regions, identifying critical genetic variations, mutations, and alterations associated with various hereditary conditions, oncological malignancies, and rare genetic disorders. Developed and executed by the specialized Gene-Tech division of Chughtai Lab, this panel offers an in-depth examination of the patient's DNA, providing clinicians with actionable insights to guide therapeutic decisions, estimate disease prognosis, and assess familial risk profiles.

Next-Generation Sequencing has revolutionized the field of medical genetics by allowing the simultaneous sequencing of multiple genes of interest with high analytical sensitivity and specificity. The Orion Focus Panel targets a curated set of clinically relevant genes, bypassing the need for sequential single-gene testing, which is often time-consuming and costly. By evaluating both somatic mutations (acquired during a person's lifetime) and germline mutations (inherited from parents), this panel serves as a cornerstone for precision oncology and clinical genetics. The genomic data generated is processed through advanced bioinformatics pipelines, comparing the patient's genetic sequence against global reference databases to identify pathogenic, likely pathogenic, or benign variants.

The clinical utility of the Orion Focus Panel lies in its ability to deliver personalized diagnostic answers. In oncology, for instance, identifying specific genetic drivers enables oncologists to prescribe targeted therapies that specifically attack cancer cells with those mutations, minimizing damage to healthy tissues and improving overall survival rates. Beyond oncology, the panel assists in diagnosing complex, multi-system genetic disorders that present with overlapping symptoms, allowing for early intervention and tailored management plans. Chughtai Lab, with its extensive diagnostic network across Pakistan, ensures that this high-complexity molecular test is accessible to patients and clinicians nationwide, backed by expert pathologists and molecular biologists.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the Orion Focus Panel (gene-tech) at Chughtai Lab should observe the following guidelines:

• No Fasting Required: Standard dietary intake is generally permitted before sample collection, as food consumption does not alter genomic DNA sequences.
• Clinical Documentation: Patients must provide a detailed clinical history, previous pathology or genetic reports, and a completed physician requisition form indicating the specific clinical indications for the test.
• Informed Consent: Due to the sensitive nature of genetic testing, patients are required to sign an informed consent form. This document explains the scope, limitations, and potential implications of genetic findings for the patient and their family members.
• Medication History: Inform the laboratory staff of any recent blood transfusions, bone marrow transplants, or immunosuppressive therapies, as these can affect the interpretation of genetic results, particularly when using peripheral blood samples.
• Sample Type Verification: Depending on the clinical scenario, the test may require a peripheral blood sample (collected in an EDTA tube) or a formalin-fixed paraffin-embedded (FFPE) tissue block from a previous biopsy. Ensure the correct sample type is coordinated with the clinical team.

During the Procedure

The procedure for the Orion Focus Panel varies depending on whether the source material is a blood sample or a tissue specimen:

• Blood Sample Collection: If peripheral blood is used, a trained phlebotomist at Chughtai Lab will perform a standard venipuncture. A small needle is inserted into a vein, typically in the arm, to collect the required volume of blood into a sterile EDTA tube. The process takes less than five minutes and involves minimal discomfort.
• Tissue Sample Submission: For oncological cases requiring tumor profiling, the patient or clinical team must submit a representative FFPE tissue block along with the corresponding histopathology report. Chughtai Lab's pathology department reviews the block to ensure adequate tumor cell content before DNA extraction.
• Laboratory Processing: Once received by the Gene-Tech laboratory, the sample undergoes genomic DNA extraction using automated, high-precision extraction systems to ensure maximum purity and yield.
• Library Preparation and Sequencing: The extracted DNA is prepared into a genomic library, where target regions are enriched and labeled. The library is then loaded onto advanced NGS platforms for high-throughput sequencing.
• Bioinformatics Analysis: The raw sequencing data is processed using specialized bioinformatics software to detect single nucleotide variants (SNVs), small insertions/deletions (indels), and copy number variations (CNVs). Expert molecular pathologists interpret these findings in the context of the patient's clinical presentation.

When is an Orion Focus Panel (gene-tech) Performed?

Hereditary Cancer Risk Assessment

The Orion Focus Panel is frequently requested for individuals with a strong family history of malignancies, such as breast, ovarian, colorectal, or pancreatic cancers. By analyzing germline DNA, the panel identifies pathogenic variants in cancer predisposition genes (such as BRCA1, BRCA2, or mismatch repair genes). This information allows clinicians to estimate a patient's lifetime risk of developing cancer and implement aggressive surveillance protocols or prophylactic interventions to detect or prevent disease at an early, highly treatable stage.

Targeted Cancer Therapy Selection

In patients already diagnosed with advanced or metastatic malignancies, oncologists utilize the Orion Focus Panel to perform comprehensive tumor profiling. By identifying specific somatic mutations within the tumor tissue, the panel helps match patients with FDA-approved targeted therapies or clinical trials. For example, detecting specific mutations in genes like EGFR, BRAF, or KRAS can determine whether a patient will respond to specific tyrosine kinase inhibitors or monoclonal antibodies, optimizing treatment efficacy while avoiding ineffective therapies.

Evaluation of Rare Genetic Disorders

Physicians request the Orion Focus Panel when evaluating patients, particularly pediatric patients, who present with complex, unexplained clinical symptoms, developmental delays, or congenital anomalies. Because many genetic disorders share overlapping clinical features, traditional diagnostic methods can result in a prolonged diagnostic odyssey. This molecular panel screens multiple candidate genes simultaneously, helping clinicians establish a definitive genetic diagnosis, guide clinical management, and provide accurate recurrence risk counseling for the parents.

Family History Screening

When a pathogenic genetic variant has been identified in a family member (the index case), the Orion Focus Panel can be used to screen other asymptomatic relatives. This targeted familial testing determines whether other family members have inherited the same genetic risk factor. Identifying non-carriers provides reassurance and eliminates the need for unnecessary, high-cost medical surveillance, while identifying carriers allows for proactive, personalized healthcare planning and lifestyle modifications.

Monitoring Disease Progression and Resistance

In oncology, tumors constantly evolve and can acquire secondary mutations that render previously effective targeted therapies useless. The Orion Focus Panel can be performed on repeat biopsy samples or through liquid biopsy approaches to detect these resistance mutations. Identifying these genomic changes early allows oncologists to modify the treatment regimen promptly, switching to next-generation inhibitors or combination therapies to overcome drug resistance and control disease progression.

What Does an Orion Focus Panel (gene-tech) Detect?

The Orion Focus Panel (gene-tech) is designed to detect a wide spectrum of genetic alterations across clinically actionable genes. Specifically, the panel identifies:

• Single Nucleotide Variants (SNVs): Precise, single-base substitutions in the DNA sequence that can alter protein structure and function.
• Insertions and Deletions (Indels): Small additions or losses of nucleotides that can cause frameshift mutations, leading to non-functional proteins.
• Copy Number Variations (CNVs): Duplications or deletions of larger genomic regions, which can lead to gene amplification or loss of tumor suppressor function.
• BRCA1 and BRCA2 Mutations: Pathogenic variants associated with hereditary breast and ovarian cancer syndrome.
• EGFR Mutations: Activating mutations in non-small cell lung cancer that predict response to EGFR inhibitors.
• KRAS and NRAS Mutations: Predictive biomarkers in colorectal cancer that indicate resistance to anti-EGFR monoclonal antibodies.
• BRAF V600E Mutations: Key therapeutic targets in melanoma, colorectal cancer, and thyroid carcinoma.
• TP53 Alterations: Mutations in the p53 tumor suppressor gene, associated with Li-Fraumeni syndrome and aggressive tumor biology.
• Mismatch Repair (MMR) Gene Variants: Mutations in MLH1, MSH2, MSH6, and PMS2, indicative of Lynch syndrome.
• PIK3CA Mutations: Alterations that activate the PI3K/Akt/mTOR pathway, relevant in breast and gynecological cancers.
• ALK and ROS1 Gene Rearrangements: Fusion events that serve as primary therapeutic targets in lung adenocarcinoma.
• RET Proto-oncogene Mutations: Associated with Multiple Endocrine Neoplasia (MEN) type 2 and medullary thyroid carcinoma.
• APC Gene Mutations: Responsible for Familial Adenomatous Polyposis (FAP) and increased colorectal cancer risk.
• PTEN Mutations: Associated with Cowden syndrome and various sporadic cancers.
• CDH1 Mutations: Linked to hereditary diffuse gastric cancer and lobular breast cancer.
• PALB2 Variants: Partner and localizer of BRCA2, conferring increased breast cancer susceptibility.
• ATM and CHEK2 Mutations: Moderate-penetrance genes involved in DNA double-strand break repair.
• HRAS Mutations: Associated with Costello syndrome and certain somatic malignancies.
• MET Amplifications: Known resistance mechanisms in lung cancers treated with targeted therapies.
• ERBB2 (HER2) Amplifications and Mutations: Critical therapeutic targets in breast, gastric, and lung cancers.
• KIT and PDGFRA Mutations: Primary diagnostic and therapeutic markers in Gastrointestinal Stromal Tumors (GIST).
• IDH1 and IDH2 Mutations: Important prognostic and therapeutic markers in gliomas and acute myeloid leukemia.
• VHL Gene Mutations: Associated with Von Hippel-Lindau disease and clear cell renal cell carcinoma.
• WT1 Alterations: Linked to Wilms tumor and certain nephrotic syndromes.
• Variants of Uncertain Significance (VUS): Genetic alterations where the clinical impact is currently unknown based on existing medical literature.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly complex nature of Next-Generation Sequencing, bioinformatics processing, and clinical interpretation, the turnaround time for the Orion Focus Panel (gene-tech) at Chughtai Lab is typically between 14 to 21 working days. This duration ensures that every sample undergoes rigorous quality control, deep sequencing, and meticulous variant annotation by certified molecular pathologists to guarantee the highest level of clinical accuracy.

Chughtai Lab offers seamless digital access to diagnostic reports. Once the molecular pathology team signs off on the results, patients and their referring physicians receive an automated SMS notification. Reports can be viewed, downloaded, and shared instantly via the official Chughtai Lab mobile application or through the secure online portal on the Chughtai Lab website. Hard copies of the comprehensive report, which includes detailed clinical interpretations and therapeutic implications, can also be collected from any Chughtai Lab diagnostic center across Pakistan.

Orion Focus Panel (gene-tech) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Oncogene Mutation Status	Wild-type (no pathogenic mutations detected)	Pathogenic somatic mutations (e.g., EGFR, KRAS, BRAF alterations)
Tumor Suppressor Genes	Intact, functional alleles	Homozygous or heterozygous deletions, truncating mutations (e.g., TP53, PTEN)
Hereditary Cancer Susceptibility	No inherited pathogenic variants detected	Germline pathogenic variants in high-penetrance genes (e.g., BRCA1, BRCA2, MLH1)
Gene Copy Number	Diploid status (normal copy number)	Gene amplifications (e.g., ERBB2/HER2 amplification) or gene deletions
Mismatch Repair (MMR) Status	Proficient mismatch repair (pMMR)	Deficient mismatch repair (dMMR) associated with microsatellite instability
Gene Fusions / Translocations	No abnormal gene rearrangements detected	Oncogenic fusion transcripts (e.g., EML4-ALK, CD74-ROS1 fusions)
Variant Classification	Only benign or likely benign variants identified	Detection of Pathogenic, Likely Pathogenic, or Variants of Uncertain Significance (VUS)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Orion Focus Panel (gene-tech)?

• Specialized Gene-Tech Division: Dedicated molecular biology and genetics department equipped with advanced high-throughput sequencing platforms.
• Expert Pathologists and Bioinformaticians: Reports are analyzed and signed off by highly qualified molecular pathologists and bioinformatics specialists.
• Accurate Variant Annotation: Utilization of updated global genomic databases to ensure precise classification of genetic variants.
• Strict Quality Control: Adherence to international standards and rigorous internal quality assessment protocols for molecular testing.
• Comprehensive Clinical Reports: Detailed reports providing clear therapeutic, prognostic, and familial implications of the findings.
• Convenient Sample Collection: Available through Chughtai Lab's extensive network of diagnostic centers and home sample collection services across Pakistan.
• Digital Report Access: Quick and secure access to genetic reports via the Chughtai Lab mobile app and online portal.
• Patient-Focused Care: Dedicated support team to assist patients and clinicians throughout the genetic testing process, ensuring a smooth diagnostic journey.